Pinitol for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Pinitol for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A sweet plant compound from carob and soybeans that gently adjusts how cells respond to insulin. The clearest human signal is in insulin-resistant people, where it lowered fasting and longer-term blood sugar markers alongside existing treatment; the most rigorous laboratory measurement of insulin sensitivity found nothing. Safety looks unremarkable, but nothing has been studied past three months. (Full Review)

Protocol

Standard dose
1,200 mg daily
Purified D-pinitol, the dose used in both positive type 2 diabetes trials for 12–13 weeks; fatty-liver work used 300–500 mg daily
Single versus split dosing
600 mg twice daily
Split dosing matches the half-life better than once-daily and limits the unabsorbed fraction that causes digestive symptoms
Best time of day
With the two largest meals
Absorption is slowed when taken alongside carbohydrate, and the post-meal glucose effect is where the human signal is clearest
Time to effect
Fasting glucose, insulin & HOMA-IR
12 weeks
Took 12 weeks in every trial that found them
Hemoglobin A1c
12 weeks minimum
Cannot move meaningfully faster than the fasting markers
Post-meal glucose
From the first dose
Single doses leave fasting glucose unchanged, so acute meter readings mislead

Benefits

Contraindications
  • Documented soy or carob (legume) allergy matching the extract source
  • Pregnant or lactating women
  • Women actively pursuing fertility treatment
  • Chronic kidney disease stage 4 or worse (estimated glomerular filtration rate under 30 mL/min/1.73 m²)
  • Children and adolescents under 18
    •
Key Interactions
  • Insulin and insulin secretagogues (glimepiride, gliclazide, glipizide, repaglinide)
  • Metformin and other biguanides
  • Over-the-counter agents (high-dose niacin, decongestants such as pseudoephedrine, oral corticosteroids)
  • Supplement interactions (creatine monohydrate)
  • Supplements with additive glucose-lowering effect (berberine, chromium picolinate, alpha-lipoic acid, cinnamon extract, myo-inositol, D-chiro-inositol)
  • Other interventions (prolonged fasting, ketogenic or very-low-carbohydrate diets, endurance exercise blocks)
    •

Risk & Side Effects

  • Low: Digestive Discomfort at Higher Intakes; Additive Glucose Lowering Alongside Diabetes Medication; Suppressed Insulin Secretion with Raised Glucagon and Ghrelin; Blunted Lean-Mass Gains When Combined with Creatine; Legume and Soy Allergen Exposure
    •
  • Speculative: Ovarian D-chiro-inositol Overload; Uncharacterized Effects of Multi-Year Use
    •

Monitoring

Marker Target Why
Fasting glucose 75–85 mg/dL Primary glucose endpoint in every trial
Hemoglobin A1c 4.8–5.3% Three-month blood sugar average; the endpoint that separated responders
Fasting insulin 2–5 µIU/mL Detects the insulin-resistant phenotype that predicted response
HOMA-IR Below 1.0 Response predictor; benefit concentrated above 2.5
Alanine aminotransferase 10–19 U/L women, 10–26 U/L men Liver endpoint that moved in the fatty liver trial
Triglycerides Below 80 mg/dL Post-meal triglycerides fell in the liver trial
Apolipoprotein B Below 80 mg/dL The lipid marker that moved in the healthy-adult carob trial
High-sensitivity C-reactive protein Below 0.5 mg/L Tracks the inflammatory endpoint measured in obesity
Continuous glucose monitor time in range No established target for pinitol response; track change from the individual's own two-week pre-start baseline Captures the post-meal effect that fasting labs miss

Cadence: Fasting panel at baseline and again at 12 weeks, then every six months if continued; anyone taking insulin or a sulfonylurea checks fasting glucose daily for the first two weeks after starting and after any dose change.

Qualitative Assessment

  • Post-meal energy stability — whether the mid-afternoon slump after a carbohydrate-heavy lunch softens
  • Hunger and appetite pattern, given the single-dose ghrelin rise, including any increase in snacking
  • Digestive tolerance — bloating, flatulence or stool looseness, particularly in the first two weeks and after dose increases
  • Waist circumference, measured monthly at the navel, since carob preparations moved it over six weeks
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.